Founded in 2019 as the second site of Egin Research and acquired by Velocity Clinical Research in 2022, the experienced team at Velocity’s dedicated research site in North London conducts Phase 2-4 clinical trials across a broad variety of indications, including Infectious Disease, Pulmonology, Vaccines, and Women’s Health. By developing strong working relationships with local communities and having close ties with networks of cooperating practices, Velocity’s Hamburg staff provides fast, accurate patient enrolment support, even for diverse populations.
Our North London team is committed to being a resource for study volunteers, to providing the highest quality of patient care with compassion and kindness and to advancing medicine through research. With decades of research experience shared among our investigators in North London, Velocity will deliver the right patients, investigators, and research staff for your next research program.
Now Enroling in North London
Velocity is enroling participants for clinical trials in North London for the following conditions:
- Hypertriglyceridemia (High Triglycerides)
- Flu Vaccine